Tylenol is currently owned by Kenvue, an American consumer‑health company that was spun off from Johnson & Johnson in 2023.

Who actually owns Tylenol today?

  • Tylenol is made and marketed by Kenvue , which became an independent, publicly traded company under the ticker KVUE in May 2023.
  • Kenvue itself is owned by a mix of institutional investors (like Vanguard and BlackRock), individual shareholders , and company insiders, rather than a single private person.

Big‑picture corporate history

  • Tylenol was originally developed and sold under Johnson & Johnson, which separated its consumer‑health division into Kenvue in 2023.
  • As of late 2025, Kimberly‑Clark has agreed to acquire Kenvue in a roughly $48–49 billion deal, which would eventually place Tylenol under the umbrella of the combined Kimberly‑Clark–Kenvue entity, pending regulatory and shareholder approvals.

Quick‑reference ownership snapshot

Entity| Role regarding Tylenol| Status (as of early 2026)
---|---|---
Kenvue| Current maker and brand owner| Independent public company; parent of Tylenol. 13
Johnson & Johnson| Former parent company| No longer directly owns Tylenol after the 2023 spin‑off. 13
Kimberly‑Clark| Acquirer in planned deal| Negotiating to buy Kenvue; deal not yet closed. 357

So if someone asks “who owns Tylenol,” the clean answer is: Kenvue , with ownership spread across public‑market shareholders and major investment firms.

Information gathered from public forums or data available on the internet and portrayed here.